{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:49:54Z","timestamp":1785890994143,"version":"3.56.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Fujian","award":["2024J011219"],"award-info":[{"award-number":["2024J011219"]}]},{"name":"the Natural Science Foundation of Fujian","award":["2024J011163"],"award-info":[{"award-number":["2024J011163"]}]},{"name":"Fujian Province Joint Funds for the Innovation of Science and Technology","award":["2025Y9481"],"award-info":[{"award-number":["2025Y9481"]}]},{"name":"Fujian Young Healthcare Talent Development Program","award":["2025GGA083"],"award-info":[{"award-number":["2025GGA083"]}]},{"name":"Fuzhou Sci-Tech Talent Cultivation Project","award":["2025R012"],"award-info":[{"award-number":["2025R012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05075-5","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:15:47Z","timestamp":1780053347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal stem cells and extracellular vesicles for MAFLD: from biological mechanisms to translational prospects"],"prefix":"10.1186","volume":"17","author":[{"given":"Zhennan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naishun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"5075_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"5075_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11901-023-00620-9","volume":"22","author":"MM Ram\u00edrez-Mej\u00eda","year":"2023","unstructured":"Ram\u00edrez-Mej\u00eda MM, M\u00e9ndez-S\u00e1nchez N. What Is in a Name: from NAFLD to MAFLD and MASLD\u2014Unraveling the Complexities and Implications. Curr Hepatol Rep. 2023;22(4):221\u20137.","journal-title":"Curr Hepatol Rep"},{"key":"5075_CR3","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.37349\/edd.2025.100586","volume":"4","author":"A Lonardo","year":"2025","unstructured":"Lonardo A, Zheng M-H, Eslam M. MASLD vs. MAFLD. A narrative review. Explor Dig Dis. 2025;4:100586.","journal-title":"Explor Dig Dis"},{"issue":"2","key":"5075_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","volume":"83","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Valvano CM, De Nardo W, Watt MJ. Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms. J Hepatol. 2025;83(2):584\u201395.","journal-title":"J Hepatol"},{"key":"5075_CR5","doi-asserted-by":"publisher","first-page":"204201882211455","DOI":"10.1177\/20420188221145549","volume":"14","author":"RM Pipitone","year":"2023","unstructured":"Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145549.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"Suppl 2","key":"5075_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12072-024-10704-3","volume":"18","author":"Y Fouad","year":"2024","unstructured":"Fouad Y, Alboraie M, Shiha G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024;18(Suppl 2):827\u201333.","journal-title":"Hepatol Int"},{"key":"5075_CR7","doi-asserted-by":"publisher","first-page":"1291501","DOI":"10.3389\/fmed.2024.1291501","volume":"11","author":"M Habibullah","year":"2024","unstructured":"Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Front Med (Lausanne). 2024;11:1291501.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"5075_CR8","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.jhep.2024.03.039","volume":"81","author":"XD Zhou","year":"2024","unstructured":"Zhou XD, Lonardo A, Pan CQ, Shapiro MD, Zheng MH, Group WMCRW. Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both. J Hepatol. 2024;81(4):e157\u20139.","journal-title":"J Hepatol"},{"issue":"2","key":"5075_CR9","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/j.jhep.2023.08.003","volume":"80","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and\/or MAFLD. J Hepatol. 2024;80(2):e62\u20134.","journal-title":"J Hepatol"},{"issue":"1","key":"5075_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","volume":"103","author":"I Pierantonelli","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2019;103(1):e1\u201313.","journal-title":"Transplantation"},{"issue":"4","key":"5075_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s42000-022-00391-w","volume":"21","author":"SC Pal","year":"2022","unstructured":"Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Horm (Athens). 2022;21(4):573\u201389.","journal-title":"Horm (Athens)"},{"key":"5075_CR12","doi-asserted-by":"publisher","first-page":"781567","DOI":"10.3389\/fmed.2021.781567","volume":"8","author":"P Torre","year":"2021","unstructured":"Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Front Med (Lausanne). 2021;8:781567.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"5075_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.14218\/JCTH.2022.00067","volume":"10","author":"K Clare","year":"2022","unstructured":"Clare K, Dillon JF, Brennan PN. Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD. J Clin Transl Hepatol. 2022;10(5):939\u201346.","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"5075_CR14","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1111\/jcmm.16338","volume":"25","author":"L Li","year":"2021","unstructured":"Li L, Zeng X, Liu Z, Chen X, Li L, Luo R, et al. Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. J Cell Mol Med. 2021;25(6):2976\u201393.","journal-title":"J Cell Mol Med"},{"key":"5075_CR15","doi-asserted-by":"crossref","unstructured":"Ramai D, Facciorusso A, Vigandt E, Schaf B, Saadedeen W, Chauhan A et al. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells. 2021;10(12).","DOI":"10.3390\/cells10123401"},{"key":"5075_CR16","doi-asserted-by":"crossref","unstructured":"Kholodenko IV, Yarygin KN. Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis. Biomedicines. 2023;11(11).","DOI":"10.3390\/biomedicines11113056"},{"key":"5075_CR17","doi-asserted-by":"crossref","unstructured":"Guo Q, Li Y, Dai X, Wang B, Zhang J, Cao H. Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD). Nutrients. 2023;15(17).","DOI":"10.3390\/nu15173722"},{"key":"5075_CR18","doi-asserted-by":"publisher","first-page":"114686","DOI":"10.1016\/j.intimp.2025.114686","volume":"156","author":"SK Mahmoudi","year":"2025","unstructured":"Mahmoudi SK, Abdolahi S, Saniee P, Zali MR, Hatami B, Baghaei K. Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: A novel approach to alleviate inflammation in NASH pathogenesis. Int Immunopharmacol. 2025;156:114686.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"5075_CR19","first-page":"CD015033","volume":"10","author":"H Wen","year":"2024","unstructured":"Wen H, Deng H, Yang L, Li L, Lin J, Zheng P, et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;10(10):CD015033.","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"5075_CR20","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385.","journal-title":"N Engl J Med"},{"issue":"4","key":"5075_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s13340-025-00833-x","volume":"16","author":"S Mondal","year":"2025","unstructured":"Mondal S, Chowdhury AS, Deb R, Sanyal D. Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future. Diabetol Int. 2025;16(4):678\u201397.","journal-title":"Diabetol Int"},{"issue":"1","key":"5075_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-023-03586-1","volume":"80","author":"M Zachou","year":"2024","unstructured":"Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, et al. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. Eur J Clin Pharmacol. 2024;80(1):127\u201350.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"5075_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jcag\/gwae057","volume":"8","author":"KJ Potter","year":"2025","unstructured":"Potter KJ, Phinney J, Kulai T, Munro V. Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Can Assoc Gastroenterol. 2025;8(2):47\u201357.","journal-title":"J Can Assoc Gastroenterol"},{"issue":"9","key":"5075_CR24","first-page":"802","volume":"12","author":"Y Hu","year":"2024","unstructured":"Hu Y, Sun C, Chen Y, Liu YD, Fan JG. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease\/Metabolic Dysfunction-associated Steatotic Liver Disease. J Clin Transl Hepatol. 2024;12(9):802\u201314.","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"5075_CR25","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754\u201367.","journal-title":"Hepatology"},{"issue":"3","key":"5075_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","volume":"72","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, et al. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020;72(3):892\u2013905.","journal-title":"Hepatology"},{"issue":"2","key":"5075_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med. 2022;292(2):190\u2013204.","journal-title":"J Intern Med"},{"issue":"2","key":"5075_CR28","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","volume":"77","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC, Yu J. Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options. Pharmacol Rev. 2025;77(2):100018.","journal-title":"Pharmacol Rev"},{"issue":"12","key":"5075_CR29","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/apt.70196","volume":"61","author":"M Zafer","year":"2025","unstructured":"Zafer M, Tavaglione F, Romero-Gomez M, Loomba R, Review Article. GLP-1 Receptor Agonists and Glucagon\/GIP\/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Aliment Pharmacol Ther. 2025;61(12):1872\u201388.","journal-title":"Aliment Pharmacol Ther"},{"key":"5075_CR30","doi-asserted-by":"crossref","unstructured":"Boldys A, Buldak L, Maliglowka M, Surma S, Okopien B. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Med (Kaunas). 2023;59(10).","DOI":"10.3390\/medicina59101789"},{"issue":"8","key":"5075_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4252\/wjsc.v16.i8.780","volume":"16","author":"CH Cheng","year":"2024","unstructured":"Cheng CH, Hao WR, Cheng TH. Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease. World J Stem Cells. 2024;16(8):780\u20133.","journal-title":"World J Stem Cells"},{"issue":"7","key":"5075_CR32","doi-asserted-by":"publisher","first-page":"760","DOI":"10.4252\/wjsc.v16.i7.760","volume":"16","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Yusoff NM, Du J, Moses EJ, Lin JT. Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease. World J Stem Cells. 2024;16(7):760\u201372.","journal-title":"World J Stem Cells"},{"key":"5075_CR33","doi-asserted-by":"publisher","first-page":"3919002","DOI":"10.1155\/2023\/3919002","volume":"2023","author":"S Yi","year":"2023","unstructured":"Yi S, Cong Q, Zhu Y, Xu Q. Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease. Stem Cells Int. 2023;2023:3919002.","journal-title":"Stem Cells Int"},{"issue":"5","key":"5075_CR34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1007\/s12015-023-10539-9","volume":"19","author":"G Yang","year":"2023","unstructured":"Yang G, Fan X, Liu Y, Jie P, Mazhar M, Liu Y, et al. Immunomodulatory Mechanisms and Therapeutic Potential of Mesenchymal Stem Cells. Stem Cell Rev Rep. 2023;19(5):1214\u201331.","journal-title":"Stem Cell Rev Rep"},{"key":"5075_CR35","doi-asserted-by":"publisher","first-page":"637725","DOI":"10.3389\/fcell.2021.637725","volume":"9","author":"L Muller","year":"2021","unstructured":"Muller L, Tunger A, Wobus M, von Bonin M, Towers R, Bornhauser M, et al. Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update. Front Cell Dev Biol. 2021;9:637725.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"5075_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13287-024-04127-y","volume":"16","author":"WC Huang","year":"2025","unstructured":"Huang WC, Li YC, Chen PX, Ma KS, Wang LT. Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials. Stem Cell Res Ther. 2025;16(1):3.","journal-title":"Stem Cell Res Ther"},{"key":"5075_CR37","doi-asserted-by":"crossref","unstructured":"Zhang B, Zhang B, Lai RC, Sim WK, Lam KP, Lim SK. MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH. Int J Mol Sci. 2023;24(9).","DOI":"10.3390\/ijms24098092"},{"issue":"1","key":"5075_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13287-025-04855-9","volume":"17","author":"H Zhang","year":"2025","unstructured":"Zhang H, Liu P, Deng Y, Wu L, Fan O, Cui Y, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate non-alcoholic fatty liver disease via activating TFEB-mediated autophagy in male mice. Stem Cell Res Ther. 2025;17(1):34.","journal-title":"Stem Cell Res Ther"},{"key":"5075_CR39","doi-asserted-by":"crossref","unstructured":"Nickel S, Christ M, Schmidt S, Kosacka J, Kuhne H, Roderfeld M et al. Human Mesenchymal Stromal Cells Resolve Lipid Load in High Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation. Cells. 2022;11(11).","DOI":"10.3390\/cells11111829"},{"issue":"1","key":"5075_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13287-025-04874-6","volume":"17","author":"W Zhang","year":"2025","unstructured":"Zhang W, Xie Y, Wang B. Senescence of bone marrow mesenchymal stromal cells: a narrative review of mechanisms, functional consequences, and rejuvenation strategies for age-related disorders. Stem Cell Res Ther. 2025;17(1):58.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5075_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13287-022-03041-5","volume":"13","author":"P Liu","year":"2022","unstructured":"Liu P, Mao Y, Xie Y, Wei J, Yao J. Stem cells for treatment of liver fibrosis\/cirrhosis: clinical progress and therapeutic potential. Stem Cell Res Ther. 2022;13(1):356.","journal-title":"Stem Cell Res Ther"},{"key":"5075_CR42","doi-asserted-by":"publisher","first-page":"1558194","DOI":"10.3389\/fendo.2025.1558194","volume":"16","author":"D Qin","year":"2025","unstructured":"Qin D, Huang P, Chen J, Wu C, Liang Y. The therapeutic potential of different mesenchymal stem cells and their derived exosomes in metabolic dysfunction-associated steatotic liver disease. Front Endocrinol (Lausanne). 2025;16:1558194.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5075_CR43","doi-asserted-by":"publisher","first-page":"102425","DOI":"10.1016\/j.scr.2021.102425","volume":"54","author":"K Ishida","year":"2021","unstructured":"Ishida K, Seki A, Kawaguchi K, Nasti A, Yamato M, Inui H, et al. Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. Stem Cell Res. 2021;54:102425.","journal-title":"Stem Cell Res"},{"issue":"5","key":"5075_CR44","first-page":"334","volume":"50","author":"Z Moayedfard","year":"2025","unstructured":"Moayedfard Z, Bagheri Lankarani K, Alizadeh AA, Nekooeian AA, Dara M, Koohpeyma F, et al. The Ameliorative Effect of Adipose-Derived Mesenchymal Stem Cells and Their Exosomes in Non-alcoholic Steatohepatitis by Simultaneously Enhancing Autophagic Flux and Suppressing Endoplasmic Reticulum Stress. Iran J Med Sci. 2025;50(5):334\u201350.","journal-title":"Iran J Med Sci"},{"issue":"3","key":"5075_CR45","doi-asserted-by":"publisher","first-page":"e25460","DOI":"10.1016\/j.heliyon.2024.e25460","volume":"10","author":"J Hu","year":"2024","unstructured":"Hu J, Li S, Zhong X, Wei Y, Sun Q, Zhong L. Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice. Heliyon. 2024;10(3):e25460.","journal-title":"Heliyon"},{"issue":"5","key":"5075_CR46","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.4252\/wjsc.v17.i5.105266","volume":"17","author":"KB Zhou","year":"2025","unstructured":"Zhou KB, Nie L, Wang ML, Xiao DH, Zhang HY, Yang X, et al. Human umbilical cord mesenchymal stem cells ameliorate liver metabolism in diabetic rats with metabolic-associated fatty liver disease. World J Stem Cells. 2025;17(5):105266.","journal-title":"World J Stem Cells"},{"issue":"1","key":"5075_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13287-023-03476-4","volume":"14","author":"S Yu","year":"2023","unstructured":"Yu S, Yu S, Liu H, Liao N, Liu X. Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases. Stem Cell Res Ther. 2023;14(1):235.","journal-title":"Stem Cell Res Ther"},{"key":"5075_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbrc.2021.01.098","volume":"546","author":"M Yang","year":"2021","unstructured":"Yang M, Cui Y, Song J, Cui C, Wang L, Liang K, et al. Mesenchymal stem cell-conditioned medium improved mitochondrial function and alleviated inflammation and apoptosis in non-alcoholic fatty liver disease by regulating SIRT1. Biochem Biophys Res Commun. 2021;546:74\u201382.","journal-title":"Biochem Biophys Res Commun"},{"key":"5075_CR49","doi-asserted-by":"publisher","first-page":"4639115","DOI":"10.1155\/sci\/4639115","volume":"2025","author":"R Hu","year":"2025","unstructured":"Hu R, Zhao J, Cheng Y, Su W, Ren R, Zhang H, et al. Exogenous Mitochondrial Pretreatment Enhances the Therapeutic Effect of UC-MSCs on NAFLD in Type 2 Diabetic Mice by Mediating Mitochondrial Transfer. Stem Cells Int. 2025;2025:4639115.","journal-title":"Stem Cells Int"},{"key":"5075_CR50","doi-asserted-by":"publisher","first-page":"833878","DOI":"10.3389\/fimmu.2022.833878","volume":"13","author":"R Wu","year":"2022","unstructured":"Wu R, Fan X, Wang Y, Shen M, Zheng Y, Zhao S, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. Front Immunol. 2022;13:833878.","journal-title":"Front Immunol"},{"key":"5075_CR51","doi-asserted-by":"publisher","first-page":"1612589","DOI":"10.3389\/fcell.2025.1612589","volume":"13","author":"T Zhang","year":"2025","unstructured":"Zhang T, Zhang L, Ma X, Song W. The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics. Front Cell Dev Biol. 2025;13:1612589.","journal-title":"Front Cell Dev Biol"},{"key":"5075_CR52","doi-asserted-by":"publisher","first-page":"1322514","DOI":"10.3389\/fbioe.2023.1322514","volume":"11","author":"L Zheng","year":"2023","unstructured":"Zheng L, Gong H, Zhang J, Guo L, Zhai Z, Xia S, et al. Strategies to improve the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease. Front Bioeng Biotechnol. 2023;11:1322514.","journal-title":"Front Bioeng Biotechnol"},{"issue":"06","key":"5075_CR53","first-page":"571","volume":"45","author":"J Zhao","year":"2024","unstructured":"Zhao J, Wang Y, Hou Y, Ma W, Mu Y, Gu W. Efficacy of UC-MSC infusion in patients with coexisting type 2 diabetes mellitus and nonalcoholic fatty liver disease: A post hoc analysis of a prospective clinical trial. Acad J Chin PLA Med Sch. 2024;45(06):571. 7,83 (In Chinese).","journal-title":"Acad J Chin PLA Med Sch"},{"key":"5075_CR54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.reth.2021.04.003","volume":"18","author":"Y Sakai","year":"2021","unstructured":"Sakai Y, Fukunishi S, Takamurai M, Kawaguchi K, Inoue O, Usui S, et al. Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. Regen Ther. 2021;18:97\u2013101.","journal-title":"Regen Ther"},{"issue":"1","key":"5075_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13287-025-04821-5","volume":"17","author":"Y Liu","year":"2025","unstructured":"Liu Y, Li J, Su W, Wang S. Stem cell therapy: a novel frontier in the treatment of liver fibrosis\/cirrhosis. Stem Cell Res Ther. 2025;17(1):4.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5075_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13287-024-03943-6","volume":"15","author":"F Wen","year":"2024","unstructured":"Wen F, Yang G, Yu S, Liu H, Liao N, Liu Z. Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties. Stem Cell Res Ther. 2024;15(1):320.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"5075_CR57","doi-asserted-by":"publisher","first-page":"162624","DOI":"10.1016\/j.jpedsurg.2025.162624","volume":"60","author":"TL Nguyen","year":"2025","unstructured":"Nguyen TL, Nguyen HP, Bui TH, Phan TKT, Ngo DM, Ha TTH, et al. Outcomes of Allogeneic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation. J Pediatr Surg. 2025;60(11):162624.","journal-title":"J Pediatr Surg"},{"key":"5075_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001509","author":"FA Anania","year":"2025","unstructured":"Anania FA, Hager R, Higgins K, Makar GA, Siegel J, Tran TT. Non-invasive tests: Establishing efficacy for metabolic dysfunction\u2013associated steatohepatitis beyond the biopsy\u2014Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001509.","journal-title":"Hepatology"},{"key":"5075_CR59","doi-asserted-by":"crossref","unstructured":"Rinella ME, Sookoian S. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nature Reviews Gastroenterology & Hepatology; 2026.","DOI":"10.1038\/s41575-026-01187-8"},{"issue":"4","key":"5075_CR60","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/HEP.0000000000001421","volume":"83","author":"F Ravaioli","year":"2026","unstructured":"Ravaioli F. Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST. Hepatology. 2026;83(4):701\u20134.","journal-title":"Hepatology"},{"issue":"1","key":"5075_CR61","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13287-023-03287-7","volume":"14","author":"A Lotfy","year":"2023","unstructured":"Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal\/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023;14(1):66.","journal-title":"Stem Cell Res Ther"},{"key":"5075_CR62","doi-asserted-by":"publisher","first-page":"8628027","DOI":"10.1155\/2019\/8628027","volume":"2019","author":"B Li","year":"2019","unstructured":"Li B, Cheng Y, Yu S, Zang L, Yin Y, Liu J. Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice. Stem Cells Int. 2019;2019:8628027.","journal-title":"Stem Cells Int"},{"issue":"3","key":"5075_CR63","first-page":"3769","volume":"17","author":"H Wang","year":"2018","unstructured":"Wang H, Zhang H, Huang B, Miao G, Yan X, Gao G, et al. Mesenchymal stem cells reverse high\u2013fat diet\u2013induced non\u2013alcoholic fatty liver disease through suppression of CD4\u2009+\u2009T lymphocytes in mice. Mol Med Rep. 2018;17(3):3769\u201374.","journal-title":"Mol Med Rep"},{"issue":"1","key":"5075_CR64","doi-asserted-by":"publisher","first-page":"18778","DOI":"10.1038\/s41598-021-98254-8","volume":"11","author":"H Muto","year":"2021","unstructured":"Muto H, Ito T, Tanaka T, Yokoyama S, Yamamoto K, Imai N, et al. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. Sci Rep. 2021;11(1):18778.","journal-title":"Sci Rep"},{"issue":"2","key":"5075_CR65","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/stmcls\/sxac091","volume":"41","author":"J Du","year":"2023","unstructured":"Du J, Jiang Y, Liu X, Ji X, Xu B, Zhang Y, et al. HGF Secreted by Menstrual Blood-Derived Endometrial Stem Cells Ameliorates Non-Alcoholic Fatty Liver Disease Through Downregulation of Hepatic Rnf186. Stem Cells. 2023;41(2):153\u201368.","journal-title":"Stem Cells"},{"issue":"1","key":"5075_CR66","doi-asserted-by":"publisher","first-page":"e134807","DOI":"10.5812\/ijpr-134807","volume":"22","author":"R Afarin","year":"2023","unstructured":"Afarin R, Aslani F, Asadizade S, Jaberian Asl B, Mohammadi Gahrooie M, Shakerian E, et al. The Effect of Lipopolysaccharide-Stimulated Adipose-Derived Mesenchymal Stem Cells on NAFLD Treatment in High-Fat Diet-Fed Rats. Iran J Pharm Res. 2023;22(1):e134807.","journal-title":"Iran J Pharm Res"},{"key":"5075_CR67","doi-asserted-by":"publisher","first-page":"101382","DOI":"10.1016\/j.tice.2020.101382","volume":"66","author":"X Xu","year":"2020","unstructured":"Xu X, Wang W, Lin L, Chen P. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4\/NF-kB inflammatory pathway and oxidative stress in T2DM\/NAFLD rats. Tissue Cell. 2020;66:101382.","journal-title":"Tissue Cell"},{"issue":"1","key":"5075_CR68","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12964-024-01950-x","volume":"22","author":"C Zhang","year":"2024","unstructured":"Zhang C, Ji J, Du X, Zhang L, Song Y, Wang Y, et al. Atg5-deficient mesenchymal stem cells protect against non-alcoholic fatty liver by accelerating hepatocyte growth factor secretion. Cell Commun Signal. 2024;22(1):579.","journal-title":"Cell Commun Signal"},{"key":"5075_CR69","doi-asserted-by":"crossref","unstructured":"El-Derany MO, AbdelHamid SG. Bone Marrow Mesenchymal Stem Cells and Their Derived Extracellular Vesicles Attenuate Non-Alcoholic Steatohepatitis-Induced Cardiotoxicity via Modulating Cardiac Mechanisms. Life (Basel). 2022;12(3).","DOI":"10.3390\/life12030355"},{"key":"5075_CR70","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.reth.2020.03.012","volume":"14","author":"T Watanabe","year":"2020","unstructured":"Watanabe T, Tsuchiya A, Takeuchi S, Nojiri S, Yoshida T, Ogawa M, et al. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. Regen Ther. 2020;14:252\u201361.","journal-title":"Regen Ther"},{"key":"5075_CR71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.reth.2021.11.005","volume":"18","author":"M Yano","year":"2021","unstructured":"Yano M, Nasti A, Seki A, Ishida K, Yamato M, Inui H, et al. Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. Regen Ther. 2021;18:497\u2013507.","journal-title":"Regen Ther"},{"issue":"1","key":"5075_CR72","first-page":"174","volume":"11","author":"J Ji","year":"2023","unstructured":"Ji J, Wu L, Wei J, Wu J, Guo C. The Gut Microbiome and Ferroptosis in MAFLD. J Clin Transl Hepatol. 2023;11(1):174\u201387.","journal-title":"J Clin Transl Hepatol"},{"issue":"21","key":"5075_CR73","doi-asserted-by":"publisher","first-page":"21660","DOI":"10.18632\/aging.103962","volume":"12","author":"Z Yang","year":"2020","unstructured":"Yang Z, Xia Q, Lu D, Yue H, Zhang J, Li Y, et al. Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis. Aging. 2020;12(21):21660\u201373.","journal-title":"Aging"},{"key":"5075_CR74","first-page":"8573","volume":"19","author":"M Zeng","year":"2024","unstructured":"Zeng M, Liu M, Tao X, Yin X, Shen C, Wang X. Emerging Trends in the Application of Extracellular Vesicles as Novel Oral Delivery Vehicles for Therapeutics in Inflammatory Diseases. Int J Nanomed. 2024;19:8573\u2013601.","journal-title":"Int J Nanomed"},{"key":"5075_CR75","doi-asserted-by":"crossref","unstructured":"Guan X, Zhu M, Zhu H, Wang Q, Chen J, Chen Y et al. Oral natural extracellular vesicles for biomedical applications: Advances and clinical perspectives. J Adv Res. 2025.","DOI":"10.1016\/j.jare.2025.08.003"},{"key":"5075_CR76","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425\u201356.","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"5075_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"5075_CR78","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","volume":"68","author":"PK Santhekadur","year":"2018","unstructured":"Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2018;68(2):230\u20137.","journal-title":"J Hepatol"},{"issue":"1","key":"5075_CR79","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13287-025-04197-6","volume":"16","author":"W Jiang","year":"2025","unstructured":"Jiang W, Zeng Q, Liu CH, Wang Y, Wang S, Chen E, et al. Huc-MSCs-derived exosomes alleviate non-alcoholic steatohepatitis by regulating macrophages polarization through miR-24-3p\/STING axis. Stem Cell Res Ther. 2025;16(1):74.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"5075_CR80","doi-asserted-by":"publisher","first-page":"114325","DOI":"10.1016\/j.yexcr.2024.114325","volume":"443","author":"A Wang","year":"2024","unstructured":"Wang A, Li B, Su W, Zhang H, Hu R, Zhang Y, et al. Exosomes derived from diabetic microenvironment-preconditioned mesenchymal stem cells ameliorate nonalcoholic fatty liver disease and inhibit pyroptosis of hepatocytes. Exp Cell Res. 2024;443(2):114325.","journal-title":"Exp Cell Res"},{"key":"5075_CR81","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bbrc.2022.11.012","volume":"637","author":"X Du","year":"2022","unstructured":"Du X, Li H, Han X, Ma W. Mesenchymal stem cells-derived exosomal miR-24-3p ameliorates non-alcohol fatty liver disease by targeting Keap-1. Biochem Biophys Res Commun. 2022;637:331\u201340.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"5075_CR82","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s13287-022-03201-7","volume":"13","author":"Y Shi","year":"2022","unstructured":"Shi Y, Yang X, Wang S, Wu Y, Zheng L, Tang Y, et al. Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model. Stem Cell Res Ther. 2022;13(1):517.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"5075_CR83","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s13577-021-00593-1","volume":"34","author":"L Cheng","year":"2021","unstructured":"Cheng L, Yu P, Li F, Jiang X, Jiao X, Shen Y, et al. Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression. Hum Cell. 2021;34(6):1697\u2013708.","journal-title":"Hum Cell"},{"key":"5075_CR84","doi-asserted-by":"publisher","first-page":"114624","DOI":"10.1016\/j.bcp.2021.114624","volume":"190","author":"MO El-Derany","year":"2021","unstructured":"El-Derany MO, AbdelHamid SG. Upregulation of miR-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition. Biochem Pharmacol. 2021;190:114624.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5075_CR85","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2018.11.189","volume":"508","author":"L Jiang","year":"2019","unstructured":"Jiang L, Zhang S, Hu H, Yang J, Wang X, Ma Y, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acute liver failure by reducing the activity of the NLRP3 inflammasome in macrophages. Biochem Biophys Res Commun. 2019;508(3):735\u201341.","journal-title":"Biochem Biophys Res Commun"},{"key":"5075_CR86","doi-asserted-by":"publisher","first-page":"101837","DOI":"10.1016\/j.trim.2023.101837","volume":"78","author":"GA Tawfeek","year":"2023","unstructured":"Tawfeek GA, Kasem HA. Curcumin preconditioned mesenchymal stem cells derived exosomes transplantation ameliorate and protect against non- alcoholic steatohepatitis by regulation the expression of key genes of inflammation and oxidative stress. Transpl Immunol. 2023;78:101837.","journal-title":"Transpl Immunol"},{"issue":"7","key":"5075_CR87","doi-asserted-by":"publisher","first-page":"e70125","DOI":"10.1002\/jev2.70125","volume":"14","author":"M Du","year":"2025","unstructured":"Du M, Yang H, Niu J, Huang J, Wang L, Xi J, et al. Umbilical Cord-Mesenchymal Stromal Cell-Derived Extracellular Vesicles Target the Liver to Improve Neurovascular Health in Type 2 Diabetes With Non-Alcoholic Fatty Liver Disease. J Extracell Vesicles. 2025;14(7):e70125.","journal-title":"J Extracell Vesicles"},{"key":"5075_CR88","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.freeradbiomed.2024.04.214","volume":"219","author":"Y Chen","year":"2024","unstructured":"Chen Y, Yang F, Shi Y, Sheng J, Wang Y, Zhang L, et al. RNF31 alleviates liver steatosis by promoting p53\/BNIP3-related mitophagy in hepatocytes. Free Radic Biol Med. 2024;219:163\u201379.","journal-title":"Free Radic Biol Med"},{"key":"5075_CR89","doi-asserted-by":"crossref","unstructured":"Kim J, Lee SK, Jeong SY, You H, Han SD, Park S et al. Multifaceted action of stem cell-derived extracellular vesicles for nonalcoholic steatohepatitis. J Control Release. 2023.","DOI":"10.1016\/j.jconrel.2023.10.045"},{"issue":"7","key":"5075_CR90","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.jhepr.2023.100746","volume":"5","author":"F Yang","year":"2023","unstructured":"Yang F, Wu Y, Chen Y, Xi J, Chu Y, Jin J, et al. Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis. JHEP Rep. 2023;5(7):100746.","journal-title":"JHEP Rep"},{"issue":"1","key":"5075_CR91","doi-asserted-by":"publisher","first-page":"18431","DOI":"10.1038\/s41598-023-45828-3","volume":"13","author":"C Liang","year":"2023","unstructured":"Liang C, Gao S, Gao J, Xu Y, Li Q. Comparison of effects of HucMSCs, exosomes, and conditioned medium on NASH. Sci Rep. 2023;13(1):18431.","journal-title":"Sci Rep"},{"issue":"10","key":"5075_CR92","doi-asserted-by":"publisher","first-page":"e0333698","DOI":"10.1371\/journal.pone.0333698","volume":"20","author":"BF Alowaiesh","year":"2025","unstructured":"Alowaiesh BF, Ibrahim D, Saleh AA, Alhaithloul HAS, Alkhaldi AAM, Abdelfattah-Hassan A. Exosomes combined with extra virgin olive oil reduces lipogenesis, oxidative stress, and inflammation in non-alcoholic fatty liver disease model. PLoS ONE. 2025;20(10):e0333698.","journal-title":"PLoS ONE"},{"issue":"1","key":"5075_CR93","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/21623945.2022.2098583","volume":"11","author":"Q Niu","year":"2022","unstructured":"Niu Q, Wang T, Wang Z, Wang F, Huang D, Sun H, et al. Adipose-derived mesenchymal stem cell-secreted extracellular vesicles alleviate non-alcoholic fatty liver disease via delivering miR-223-3p. Adipocyte. 2022;11(1):572\u201387.","journal-title":"Adipocyte"},{"key":"5075_CR94","doi-asserted-by":"publisher","first-page":"30087","DOI":"10.3402\/jev.v4.30087","volume":"4","author":"T Lener","year":"2015","unstructured":"Lener T, Gimona M, Aigner L, Borger V, Buzas E, Camussi G, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087.","journal-title":"J Extracell Vesicles"},{"issue":"6","key":"5075_CR95","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018;22(6):824\u201333.","journal-title":"Cell Stem Cell"},{"key":"5075_CR96","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/IJN.S444582","volume":"18","author":"J Tian","year":"2023","unstructured":"Tian J, Han Z, Song D, Peng Y, Xiong M, Chen Z, et al. Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications. Int J Nanomed. 2023;18:7923\u201340.","journal-title":"Int J Nanomed"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05075-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:07:27Z","timestamp":1785888447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05075-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5075"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05075-5","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"264"}}